Susan Bell Milby
Psychiatric/Mental Health · Riverton, WYNPI 1538236948
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 40 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 6 manufacturers reported payments, led by ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) at 37.3% of the total. Reporting peaked in 2023 at $405 and has fallen 76.0% since, to $97 in 2024.
Across 40 payments — averaging $21.41 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$320
- AbbVie$177
- Neurocrine Biosciences, Inc.$120
- Otsuka America Pharmaceutical, Inc.$87
- Idorsia Pharmaceuticals US Inc$78
- Teva Pharmaceuticals USA, Inc.$75
What the payments were for
- Food & beverage$856100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 14 | $320 |
| AbbVie | 9 | $177 |
| Neurocrine Biosciences, Inc. | 5 | $120 |
| Otsuka America Pharmaceutical, Inc. | 4 | $87 |
| Idorsia Pharmaceuticals US Inc | 4 | $78 |
| Teva Pharmaceuticals USA, Inc. | 4 | $75 |
How this compares
$856 in reported general payments places this provider in the 70th percentile of 76 psychiatric/mental health providers in Wyoming.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Lurasidone Hcl | 20 | $10,891 |
| Clomipramine Hcl | 12 | $2,637 |
| Quetiapine Fumarate | 58 | $2,388 |
| Dextroamphetamine-AmphetamineDextroamphetamine/Amphetamine | 27 | $1,317 |
| Divalproex Sodium ErDivalproex Sodium | 11 | $1,299 |
| Buspirone Hcl | 32 | $1,167 |
| Lamotrigine | 71 | $590 |
| Methylphenidate Hcl | 13 | $304 |
| Venlafaxine Hcl ErVenlafaxine Hcl | 26 | $260 |
| Clonazepam | 18 | $237 |
| Paroxetine Hcl | 28 | $205 |
| Risperidone | 65 | $187 |
| Duloxetine Hcl | 19 | $177 |
| Escitalopram Oxalate | 23 | $168 |
| Lorazepam | 19 | $161 |
Paid to pharmacies, not to this prescriber.
Other psychiatric/mental health in Riverton
- Dawn DubeauRiverton$81
- Janelle HoaglundCheyenne$24K
- Jennifer FraustoCasper$8K
- Michelle HipsakCasper$6K
- Rebekah LayherCasper$4K
- Teecee Hailey-FulferCasper$4K
- Timothy BarnesCheyenne$3K
- Jayme DonaldsonCasper$3K
- Karen GravesCasper$3K
- Sarah BurtCasper$3K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.